Log in
Sign up
Amprologix

Amprologix

A biotechnology and synthetic biology company developing antibiotics to treat drug-resistant bacterial infections.

OverviewStructured DataIssuesContributorsActivity
Contents

Amprologix is a University of Plymouth spin-out . Amprologix was established to develop the work of Professor Mathew Upton, professor of Medical Microbiology. The company aims to introduce new classes of antibiotics to help tackle the threat of antimicrobial resistance. Amprologix has secured industry involvement through a partnership with Ingenza. Ingenza's biologics manufacturing platform will be used to enable viable production at scale.

Ingenza is taking an equity stake in Amprologix, as is Frontier IP, a research commercialization enterprise in the U.K., and UMI3 Ltd, the research commercialization organization at University of Manchester. Frontier IP's stake in Amprologix is 10 percent, while the equity holdings by Igenza and UMI3 were not disclosed.

Amprologix is the second company founded by Upton. In 2014, he started Spectromics, based in Manchester, developing a diagnostic technology to determine appropriate dosages for antibiotics, and prevent overuse of the drugs.

Technology

Upton’s research group analyses bacteria genomes to identify patterns that offer targets for new antibiotic drugs. They discovered bacteriocins, antimicrobial peptides produced by bacteria. Epidermicin is a bacteriocin derived from natural skin bacteria. It was shown in lab rats to kill methicillin-resistant Staphylococcus aureus, or MRSA. Amprologix plans to develop other antibiotic classes and to enhance the antimicrobial properties of bacteriocins using artificial intelligence and synthetic biology approaches.

Products

Epidermicins are a new class of antibiotics capable of tackling MRSA and related superbugs at very low doses. The first product from the company is expected to be a cream containing epidermicin, which can rapidly kill harmful bacteria, including MRSA, Streptococcus and Entercoccus at very low doses.

Funding

Amprologix was awarded a £1.2 million contract from the UK Department of Health and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01. The funding, administered by Innovate UK, is intended to advance Epidermicin NI01 which is part of a new family of epidermicin-based antibiotics expected to be ready for Phase I clinical trials by early 2021. With this funding, Amprologix will optimise the formulation of Epidermicin NI01 as a cream to decolonise the nasal cavity of MRSA. A preclinical toxicology evaluation will be conducted.

Timeline

No Timeline data yet.

Funding Rounds

Open in Query Tool

Products

Open in Query Tool

Acquisitions

Open in Query Tool

SBIR/STTR Awards

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

amprologix.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Synthetic biology
Synthetic biology
Location
United Kingdom
United Kingdom
B2X
B2C
B2C
Full Address
Derriford Research Facility, Plymouth Science Park, Research Way, Plymouth PL6 8BU UK
Investors
Frontier IP Group plc
Frontier IP Group plc
-1
Founded Date
2018
Email Address
info@amprologix.com

Other attributes

Company Operating Status
Active

Find more companies like Amprologix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.